Facebook Pixel Code
About Sickkids
About SickKids

Reza Vali, M.D

The Hospital for Sick Children
Radiologist - Nuclear Medicine
Diagnostic Imaging

University of Toronto
Assistant Professor
Medical Imaging


Phone: 416-813-2488
Fax: 416-813-8389
Email: reza.vali@sickkids.ca
Alternate Contact: Caroline Robertson
Alternate Phone: 416-813-6029
Alternate Email: caroline.robertson@sickkids.ca

Brief Biography

Dr. Reza Vali has been working as an assistant professor in the Division of Nuclear Medicine since Oct. 2014.  Dr. Vali received his medical degree from Ahwaz medical university in 1995, and completed his Nuclear Medicine residency program at Tehran medical University in Iran in 2000. Subsequently, Dr. Vali completed a fellowship at the Vincent hospital in Austria in PET/CT oncology in 2007/2008. Recently, he completed his fellowship in Pediatric Nuclear Medicine in the Department of Diagnostic Imaging at The Hospital for Sick Children from Jan, 2012 to Oct, 2014. He is a member of Radiological Society of North America, Canadian Society of Nuclear Medicine, Society of Nuclear Medicine, American society of nuclear cardiology and European society of nuclear medicine.
Dr. vali’s main research interests are new radiotracers in PET and pediatric BMD including PQCT.

Projects/initiatives:
1.     F18 Coline PET/CT in the evaluation of prostate cancer.
2.     F18 FDG PET and F18 FDOPA PET for medullary cell carcinoma.
3.     I-131- MIBG: New oncologic therapy.
4.     Initiative: FLT PET for Hodgkin lymphoma (with borderline FDG SUV max ).
                        F18-FAZA in pediatric soft tissue tumor
                        PQCT in pediatric patients

Research Interests

Nuclear Medicine Imaging in thyroid cancer, PET/CT Imaging, Bone Mineral Density (BMD) including PQCT, F18-FDG PET/CT in PTLD, Brain PET for epilepsy.

Publications

Book chapters:

1. Langsteger W, Beheshti M, Vali R, Beri A, Nader M, Janetschek G. Prostate Cancer. In: Advances in Nuclear Oncology: Diagnosis and Therapy. Informa Healthcare, ISBN 9781841846149, published date: October 2007
2. Vali R, Charron M. Pediatric Renal Nuclear Medicine. Docimo, SG, Canning, DA, Khoury, AE (Supervising Editors), Austin, P, Coplen, D, Copp, H, Herndon, CDA, Lorenzo, A, Merguerian, P, Ost, M, Park, J, Shukla, A (Editors) :  THE KELALIS-KING-BELMAN TEXTBOOK OF CLINICAL PEDIATRIC UROLOGY, SIXTH EDITION
3. Vali R, Charron M. Pediatric Nuclear Oncology. Cumali Aktolun, MD, MSc, and Stanley J. Goldsmith, MD. Nuclear Oncology. Under publication (July 2014).
4. Vali R, Charron M. Nuclear Medicine in Pediatric gastrointestinal Tract. Walker’s Pediatric Gastrointestinal Disease: Physiology, Diagnosis, Management, 6thedition, Under publication.
     
Journals:

1- Vali R, Loid W, Pirich C, Langesteger W, Beheshti M. The role of F18-Choline in prostate cancer. A review article. American Journal of Nuclear Medicine.
2- Vali R, Rachmiel M, Hamilton J, El Zein M, Costantini D, Charron M. and Daneman A The accuracy of ultrasound in the follow up of paediatric patients with differentiated thyroid cancer. Pediatric Radiology.
3- Vali R,  Susan McQuattie, Daneman Alan, Amer Shammas, The value of repeat scintigraphy in patients with a high clinical suspicion for Meckel’s diverticulum after a negative or equivocal first Meckel’s scan.  Pediatric radiology.
4- Vali R, Ranson M, Harvey E, Shammas A. False-Positive In-111 DTPA Octreotide Scintigraphy in bilateral tibial stress fracture. Under publication in Pediatric Radiology.                                                                                                                                           5- Widjaja E, Shammas A, Vali R, Otsubo H, Ochi A, Snead O, Go C, Charron M. FDG-PET and magnetoencephalography in presurgical workup of children with localization-related nonlesional epilepsy. Epilepsia. 2013, Feb 8. doi: 10.1111/epi.12114.
6- Elzein M.,Vali R, Charron M, Manson D, Perlman K, Shammas A. Neuroendocrine Tumor in Liver with Positive ACTH receptor: A case report. J Pediatr Hematol Oncol. 2013, Mar 21.
7- Shammas A, Vali R, Charron M. Pediatric Nuclear Medicine in Acute Care. Semin Nucl Med. 2013 Mar.
8- Strobel K, Vali R. 18F-NAF PET/CT versus conventional bone scanning in the assessment of benign bone disease. CLINICAL UTILITY OF 18F NAF PET/CT IN BENIGN AND MALIGNANT DISORDERS. July 2012. Saunders. ISSN:1556-8598, ISBN:978-1-4557-4886-0
9- Costantini D, Vali R, Chan, J, McQuattie S, Charron M. Dual time point FDG PET/CT for the evaluation of pediatric tumors American Journal of Radiology. AJR Am J Roentgenol. 2013 Feb;200(2):408-13.
10- Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F, Nader M, Gruy B, Janetschek G, Langsteger W. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology. 2010 Mar;254(3):925-33.
11- Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J, Loidl W, Pirich C,
Fogelman I, Langsteger W. The Use of F-18 Choline PET in the Assessment of Bone Metastases in Prostate Cancer: Correlation with Morphological Changes on CT
Molecular Imaging and Biology: 2010 Jan-Feb;12(1):98-107.
12- Beheshti M, Pöcher S, Vali R, Waldenberger P, Broinger G, Nader M, Kohlfüst S, Pirich, Dralle H, Langsteger W. “ The Value of F-18 DOPA PET – CT in Patients with Medullary Thyroid Carcinoma: Comparison with F-18 FDG PET – CT.” Eur Radiol. 2009 Jun;19(6): 1425-34.        
13- Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W, Broinger G, Stoiber F, Fogelman I, Langsteger W. “ Detection of bone metastases in patients with prostate cancer by F-18 Fluorocholine and F-18 Fluoride PET - CT: A comparative study.” Eur J Nucl Med Mol I. 2008, 35(10):1766-74  
14- Beheshti M, Vali R, Langsteger W. [18F]fluorocholine PET/CT in the assessment of bone
        metastases in prostate Cancer. Eur J Nucl Med Mol I. 2007, 34(8):1316-7.                        
15- Beheshti M, Li S, Vali R, Schima W, Dudczak R, Langsteger W. “The Potential Value of F-18 FDG PET in Comparison to CT in Early Prediction of Response to Imatinib (STI571) Therapy in Patients with Gastrointestinal Stromal Tumors.” Iran J Nucl Med. 2007 ,Vol. 15, No. 2 (Serial No. 28) ISSN: 1691-2824